With the 2025 ASCO Annual Meeting (ASCO25) wrapping up today, we’re taking some time to highlight some of the innovative studies presented about hematologic malignancies. The five-day conference, which ran from May 30 through June 3, was held in Chicago, Illinois. The annual event featured oncology experts from all around the world coming together to discuss the latest insights, share emerging technologies, and network with colleagues. 

With so many research presentations at the event, we’ve created rundowns for breast cancer, hematologic malignancies, and melanoma to help you better browse through some of the exciting topics presented at ASCO25.

Nucleophosmin (NPM1) Genomic Alterations (GA) in Acute Myeloid Leukemia (AML): A Genomic Landscape Study

  • Description: NPM1 GA characterize a clinically important subset of AML cases which relapse in more than 50% of treated patients despite being generally sensitive to conventional chemo- therapy regimens. In AML, the interactions between GA in NPM1, KMT2A and menin protein have been linked to leukemogenesis and represent new potential targets for anti-tumor therapies.
  • Result: The development of menin inhibitors has recently identified GA in NPM1 as a promising target of therapy for AML patients. Other therapy targets in AML such as FLT3 and IDH1/2 are more frequently identified in NPM1mut than NPM1wt AML, while KMT2A is more frequently identified in NPM1wt AML.

Comparable Efficacy of Venetoclax 50mg with Posaconazole Versus Venetoclax 400mg in Newly Diagnosed AML Patients: A Prostpective Study of Pharmacokinetics, Toxicity, and Clinical Outcomes

  • Description: Researchers prospectively explored further dose reduction of VEN to 50mg with posaconazole and compared it with VEN 400mg with respect to pharmacokinetics, response rates, and toxicity.
  • Result: The study’s findings suggest that lower plasma levels achieved with VEN50 can lead to comparable CR rate and MRD negative rate in comparison with VEN400 with lesser myelotoxicity.

Mitoxantrone Hydrochloride Liposome Combined with Cytarabine (MA) for Patients with Newly Diagnosed Secondary Acute Myeloid Leukemia

  • Description: Researchers reported the outcomes of a novel regimen combining mitoxantrone hydrochloride liposome and cytarabine for patients with newly diagnosed secondary acute myeloid leukemia.
  • Result: The regimen demonstrated encouraging remission rates and a superior safety profile, indicating its potential as a treatment option for newly diagnosed secondary acute myeloid leukemia.

Potential Benefits of Using Different Donor for Transplantation Consolidation After Donor-Derived CD7 CAR T

  • Description: Researchers explored optimization strategies for stem cell transplantation consolidation after newly HLA-matched donor-derived CD7 CAR T therapy in relapsed or re-fractory T-cell acute lymphoblastic leukemia patients.
  • Result: The results showed that using a different donor from CD7 CAR T for subsequent stem cell transplantation may contribute to the timely clearance of CAR T cells from patients and simultaneously reduce the rate of CMV/EBV activation after stem cell infusion. In addition, the chimerism rate was slightly increased at some time points.

Brexucabtagene Autoleucel (Brexu-cel) as Consolidation Treatment in Adults with B-cell Acute Lymphoblastic Leukemia

  • Description: Brexu-cel is a CD19 CAR T cell approved for adult patients with R/R B-cell ALL. The study aimed to evaluate toxicity/efficacy in adult patients with marrow blasts <5%
  • Result: Brexu-cel CAR T expansion was observed even in pts with no morphologic disease. CAR T expansion threshold of ≥15 cells/mL could identify patients with durable RFS. Rates of G3-4 CRS/ICANS were low when brexu-cel was used as consolidation.

For a full list of abstracts, visit the official ASCO25 website.

Sign up for alerts and stay informed on the latest published guidelines and conference recaps.

Copyright © 2025 Guideline Central, all rights reserved.